Paul Schloesser – Page 5 – Endpoints News

SIGN UP

about the author

Paul Schloesser

Associate Editor

pschloesser@endpointsnews.com

Paul Schloesser on LinkedIn

Paul comes to Endpoints News as a recent graduate of the University of Missouri-Columbia, where he studied News Reporting and Political Science. Currently based in the Kansas City, Missouri area, his hobbies include cooking, doing escape rooms, and watching new TV shows. When not at his computer, he likes to check out new restaurants in his spare time.

author articles

DNA synthesis upstart raises $10M to scale operations

Last year

Judge in Astellas patent suit denies motion to bolster defendant’s case

Last year

Eiger BioPharmaceuticals to focus on GLP-1 candidate, cut workforce by 25%

Last year

Regenxbio, UPenn file patent suit against Sarepta related to new Duchenne gene therapy

Last year

K36 Therapeutics raises $70M in Series B to fund multiple myeloma research

Last year

FDA, EMA accept Pfizer's hemophilia B gene therapy, setting up showdown with CSL Behring

Last year

UK’s NICE wants more effectiveness data on Lilly’s tirzepatide

Last year

Life science VC Vertex Ventures HC raises $200M in new fund

Last year

Aldeyra says its candidate won in chronic cough PhII, setting stage for bout with Merck, GSK

Last year

UK's National Cancer Research Institute to shut down, citing 'risk of operational failure'

Last year

Sutro inks $390M royalty financing deal with Blackstone; Clinical hold on Pharvaris' HAE drug lifted

Last year

Avalo fails asthma PhII with lead candidate, shares crater

Last year

CHMP recommends AbbVie's migraine drug, GSK's anemia treatment

Last year

Jazz sues FDA, HHS over rival narcolepsy drug approval

Last year

Oncolytic virus startup Calidi secures $25M toward Series B round

Last year

MPP signs on four generics makers to make Novartis' Tasigna more accessible

Last year

Aslan outlicenses atopic dermatitis antibody in $138.5M deal

Last year

Lupin wins first FDA approval for generic version of Boehringer Ingelheim blockbuster Spiriva

Last year

UniQure unveils mixed Huntington's gene therapy data, shares tank

Last year

Novo Nordisk sues unauthorized semaglutide compounders, tempers expectations for Wegovy's global rollout

Last year

Swiss biotech unloads US rights to Duchenne candidate for $231M

Last year

UniQure reaches milestone, Idorsia's bridge financing extends runway, and Pharvaris scores $70M placement

Last year

Congress introduces two new bills about PBM reform, drug pricing

Last year

Tissue regeneration biotech raises $26M Series A to push toward clinical trials

Last year

First page Previous page 2 3 456 7 8 Next page Last page